|
1
|
Zhang K, Lu J, Mori T, Smith-Powell L,
Synold TW, Chen S and Wen W: Baicalin increases VEGF expression and
angiogenesis by activating the ERR{α}/PGC-1{α} pathway. Cardiovasc
Res. 89:426–435. 2011. View Article : Google Scholar
|
|
2
|
Carmeliet P: Angiogenesis in life, disease
and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao Y: Adipose tissue angiogenesis as a
therapeutic target for obesity and metabolic diseases. Nat Rev Drug
Discov. 9:107–115. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li WW, Li VW, Hutnik M and Chiou AS: Tumor
angiogenesis as a target for dietary cancer prevention. J Oncol.
2012:8796232012. View Article : Google Scholar
|
|
6
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grothey A and Galanis E: Targeting
angiogenesis: Progress with anti-VEGF treatment with large
molecules. Nat Rev Clin Oncol. 6:507–518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tammali R, Reddy AB, Srivastava SK and
Ramana KV: Inhibition of aldose reductase prevents angiogenesis in
vitro and in vivo. Angiogenesis. 14:209–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Folkman J: Endogenous angiogenesis
inhibitors. APMIS. 112:496–507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yi ZF, Cho SG, Zhao H, Wu YY, Luo J, Li D,
Yi T, Xu X, Wu Z and Liu M: A novel peptide from human
apolipoprotein(a) inhibits angiogenesis and tumor growth by
targeting c-Src phosphorylation in VEGF-induced human umbilical
endothelial cells. Int J Cancer. 124:843–852. 2009. View Article : Google Scholar :
|
|
11
|
Yi T, Cho SG, Yi Z, Pang X, Rodriguez M,
Wang Y, Sethi G, Aggarwal BB and Liu M: Thymoquinone inhibits tumor
angiogenesis and tumor growth through suppressing AKT and
extracellular signal-regulated kinase signaling pathways. Mol
Cancer Ther. 7:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang N, Wang L, Esko J, Giordano FJ, Huang
Y, Gerber HP, Ferrara N and Johnson RS: Loss of HIF-1alpha in
endothelial cells disrupts a hypoxia-driven VEGF autocrine loop
necessary for tumorigenesis. Cancer Cell. 6:485–495. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kane RC, Farrell AT, Saber H, Tang S,
Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, et
al: Sorafenib for the treatment of advanced renal cell carcinoma.
Clin Cancer Res. 12:7271–7278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cabebe E and Wakelee H: Sunitinib: A newly
approved small-molecule inhibitor of angiogenesis. Drugs Today
(Barc). 42:387–398. 2006. View Article : Google Scholar
|
|
16
|
Alghasham AA: Cucurbitacins - a promising
target for cancer therapy. Int J Health Sci (Qassim). 7:77–89.
2013. View
Article : Google Scholar
|
|
17
|
Molavi O, Ma Z, Mahmud A, Alshamsan A,
Samuel J, Lai R, Kwon GS and Lavasanifar A: Polymeric micelles for
the solubilization and delivery of STAT3 inhibitor cucurbitacins in
solid tumors. Int J Pharm. 347:118–127. 2008. View Article : Google Scholar
|
|
18
|
Bishayee A, Ahmed S, Brankov N and Perloff
M: Triterpenoids as potential agents for the chemoprevention and
therapy of breast cancer. Front Biosci (Landmark Ed). 16:980–996.
2011. View Article : Google Scholar
|
|
19
|
Chen JC, Chiu MH, Nie RL, Cordell GA and
Qiu SX: Cucurbitacins and cucurbitane glycosides: Structures and
biological activities. Nat Prod Rep. 22:386–399. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duangmano S, Sae-Lim P, Suksamrarn A,
Domann FE and Patmasiriwat P: Cucurbitacin B inhibits human breast
cancer cell proliferation through disruption of microtubule
polymerization and nucleophosmin/B23 translocation. BMC Complement
Altern Med. 12:1852012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dakeng S, Duangmano S, Jiratchariyakul W,
U-Pratya Y, Bögler O and Patmasiriwat P: Inhibition of Wnt
signaling by cucurbitacin B in breast cancer cells: Reduction of
Wnt-associated proteins and reduced translocation of
galectin-3-mediated β-catenin to the nucleus. J Cell Biochem.
113:49–60. 2012. View Article : Google Scholar
|
|
22
|
Liu T, Zhang M, Zhang H, Sun C and Deng Y:
Inhibitory effects of cucurbitacin B on laryngeal squamous cell
carcinoma. Eur Arch Otorhinolaryngol. 265:1225–1232. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yasuda S, Yogosawa S, Izutani Y, Nakamura
Y, Watanabe H and Sakai T: Cucurbitacin B induces G2 arrest and
apoptosis via a reactive oxygen species-dependent mechanism in
human colon adenocarcinoma SW480 cells. Mol Nutr Food Res.
54:559–565. 2010. View Article : Google Scholar
|
|
24
|
Kausar H, Munagala R, Bansal SS, Aqil F,
Vadhanam MV and Gupta RC: Cucurbitacin B potently suppresses
non-small-cell lung cancer growth: Identification of intracellular
thiols as critical targets. Cancer Lett. 332:35–45. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo D, Luo Y, He Y, Zhang H, Zhang R, Li
X, Dobrucki WL, Sinusas AJ, Sessa WC and Min W: Differential
functions of tumor necrosis factor receptor 1 and 2 signaling in
ischemia-mediated arteriogenesis and angiogenesis. Am J Pathol.
169:1886–1898. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lynch CN, Wang YC, Lund JK, Chen YW, Leal
JA and Wiley SR: TWEAK induces angiogenesis and proliferation of
endothelial cells. J Biol Chem. 274:8455–8459. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaneko T, Nagata I, Miyamoto S, Kubo H,
Kikuchi H, Fujisato T and Ikada Y: Effects of nicardipine on tube
formation of bovine vascular endothelial cells in vitro. Stroke.
23:1637–1642. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Z and Han ZC: STAT3: A critical
transcription activator in angiogenesis. Med Res Rev. 28:185–200.
2008. View Article : Google Scholar
|
|
29
|
Zhang X, Song Y, Wu Y, Dong Y, Lai L,
Zhang J, Lu B, Dai F, He L, Liu M, et al: Indirubin inhibits tumor
growth by antitumor angiogenesis via blocking VEGFR2-mediated
JAK/STAT3 signaling in endothelial cell. Int J Cancer.
129:2502–2511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boykin C, Zhang G, Chen YH, Zhang RW, Fan
XE, Yang WM and Lu Q: Cucurbitacin IIa: A novel class of anticancer
drug inducing non-reversible actin aggregation and inhibiting
survivin independent of JAK2/STAT3 phosphorylation. Br J Cancer.
104:781–789. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chan KT, Li K, Liu SL, Chu KH, Toh M and
Xie WD: Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway
in leukemia cell line K562. Cancer Lett. 289:46–52. 2010.
View Article : Google Scholar
|
|
32
|
Gupta P and Srivastava SK: Inhibition of
Integrin-HER2 signaling by cucurbitacin B leads to in vitro and in
vivo breast tumor growth suppression. Oncotarget. 5:1812–1828.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Onishi Y, Kawamoto T, Ueha T, Kishimoto K,
Hara H, Fukase N, Toda M, Harada R, Minoda M, Sakai Y, et al:
Transcutaneous application of carbon dioxide (CO2) induces
mitochondrial apoptosis in human malignant fibrous histiocytoma in
vivo. PLoS One. 7:e491892012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fesik SW: Promoting apoptosis as a
strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang L, Luo M, Liu D, Chen B, Zhang W,
Mai L, Zeng J, Huang N, Huang Y, Mo X, et al: BAD overexpression
inhibits cell growth and induces apoptosis via
mitochondrial-dependent pathway in non-small cell lung cancer.
Cancer Cell Int. 13:532013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shukla S, Sinha S, Khan S, Kumar S, Singh
K, Mitra K, Maurya R and Meeran SM: Cucurbitacin B inhibits the
stemness and metastatic abilities of NSCLC via downregulation of
canonical Wnt/β-catenin signaling axis. Sci Rep. 6:218602016.
View Article : Google Scholar
|
